Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors
- 16 February 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (4) , 1929-1939
Abstract
Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles.Keywords
This publication has 30 references indexed in Scilit:
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2011
- Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United StatesChemical Research in Toxicology, 2011
- Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guideChemical Science, 2010
- The SYK tyrosine kinase: a crucial player in diverse biological functionsNature Reviews Immunology, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor ComplexesChemical Biology & Drug Design, 2009
- Fcγ receptors as regulators of immune responsesNature Reviews Immunology, 2008
- Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: Site‐specific versus activation‐dependent survival of T cells and neutrophilsArthritis & Rheumatism, 2006
- Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitisExpert Opinion on Therapeutic Targets, 2005